125 related articles for article (PubMed ID: 12592082)
1. Bexarotene is a new treatment option for lymphomatoid papulosis.
Krathen RA; Ward S; Duvic M
Dermatology; 2003; 206(2):142-7. PubMed ID: 12592082
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
[TBL] [Abstract][Full Text] [Related]
3. Oral bexarotene in the treatment of cutaneous T-cell lymphoma.
Wong SF
Ann Pharmacother; 2001 Sep; 35(9):1056-65. PubMed ID: 11573857
[TBL] [Abstract][Full Text] [Related]
4. Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
Talpur R; Ward S; Apisarnthanarax N; Breuer-Mcham J; Duvic M
J Am Acad Dermatol; 2002 Nov; 47(5):672-84. PubMed ID: 12399758
[TBL] [Abstract][Full Text] [Related]
5. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials.
Prince HM; McCormack C; Ryan G; Baker C; Rotstein H; Davison J; Yocum R
Australas J Dermatol; 2001 May; 42(2):91-7. PubMed ID: 11309029
[TBL] [Abstract][Full Text] [Related]
6. Topical and oral bexarotene.
Schadt CR
Dermatol Ther; 2013; 26(5):400-3. PubMed ID: 24099070
[TBL] [Abstract][Full Text] [Related]
7. Effects of oral bexarotene (targretin) on the minimal erythema dose for broadspectrum UVB light.
Smit JV; De Jong EM; Van De Kerkhof PC
Skin Pharmacol Appl Skin Physiol; 2003; 16(4):237-41. PubMed ID: 12784063
[TBL] [Abstract][Full Text] [Related]
8. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial.
Heald P; Mehlmauer M; Martin AG; Crowley CA; Yocum RC; Reich SD;
J Am Acad Dermatol; 2003 Nov; 49(5):801-15. PubMed ID: 14576658
[TBL] [Abstract][Full Text] [Related]
9. Oral bexarotene for post-transplant cutaneous T-cell lymphoma.
Lewis DJ; Huang S; Duvic M
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28748653
[TBL] [Abstract][Full Text] [Related]
10. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma.
Straus DJ; Duvic M; Kuzel T; Horwitz S; Demierre MF; Myskowski P; Steckel S
Cancer; 2007 May; 109(9):1799-803. PubMed ID: 17366595
[TBL] [Abstract][Full Text] [Related]
11. Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis.
Cordel N; Tressières B; D'Incan M; Machet L; Grange F; Estève É; Dalac S; Ingen-Housz-Oro S; Bagot M; Beylot-Barry M; Joly P;
Oncologist; 2016 Jan; 21(1):76-83. PubMed ID: 26668250
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.
Breneman D; Duvic M; Kuzel T; Yocum R; Truglia J; Stevens VJ
Arch Dermatol; 2002 Mar; 138(3):325-32. PubMed ID: 11902983
[TBL] [Abstract][Full Text] [Related]
13. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
[TBL] [Abstract][Full Text] [Related]
14. Lymphomatoid papulosis localized to the face.
Dalle S; Balme B; Thomas L
Dermatol Online J; 2006 Mar; 12(3):9. PubMed ID: 16638423
[TBL] [Abstract][Full Text] [Related]
15. Bexarotene: new preparation. Cutaneous lymphoma: too many adverse effects.
Prescrire Int; 2004 Jun; 13(71):94-7. PubMed ID: 15233146
[TBL] [Abstract][Full Text] [Related]
16. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Scarisbrick JJ; Morris S; Azurdia R; Illidge T; Parry E; Graham-Brown R; Cowan R; Gallop-Evans E; Wachsmuth R; Eagle M; Wierzbicki AS; Soran H; Whittaker S; Wain EM
Br J Dermatol; 2013 Jan; 168(1):192-200. PubMed ID: 22963233
[TBL] [Abstract][Full Text] [Related]
17. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.
Duvic M; Hymes K; Heald P; Breneman D; Martin AG; Myskowski P; Crowley C; Yocum RC;
J Clin Oncol; 2001 May; 19(9):2456-71. PubMed ID: 11331325
[TBL] [Abstract][Full Text] [Related]
18. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms.
McGinnis KS; Junkins-Hopkins JM; Crawford G; Shapiro M; Rook AH; Vittorio CC
J Am Acad Dermatol; 2004 Mar; 50(3):375-9. PubMed ID: 14988678
[TBL] [Abstract][Full Text] [Related]
19. First-line treatment in lymphomatoid papulosis: a retrospective multicentre study.
Fernández-de-Misa R; Hernández-Machín B; Servitje O; Valentí-Medina F; Maroñas-Jiménez L; Ortiz-Romero PL; Sánchez Schmidt J; Pujol RM; Gallardo F; Pau-Charles I; García Muret MP; Pérez Gala S; Román C; Cañueto J; Blanch Rius L; Izu R; Ortiz-Brugués A; Martí RM; Blanes M; Morillo M; Sánchez P; Peñate Y; Bastida J; Pérez Gil A; Lopez-Lerma I; Muniesa C; Estrach T
Clin Exp Dermatol; 2018 Mar; 43(2):137-143. PubMed ID: 28994134
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata.
Talpur R; Vu J; Bassett R; Stevens V; Duvic M
J Am Acad Dermatol; 2009 Oct; 61(4):592.e1-9. PubMed ID: 19682769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
